Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A

Emicizumab is a bispecific, humanized, monoclonal antibody mimicking the factor (F) VIII cofactor activity in mediating the generation of FXa by FIXa in patients with hemophilia A (HA). This subcutaneous non-factor agent has been recently extensively approved for the prophylaxis of patients of HA pa...

Descripción completa

Detalles Bibliográficos
Autor principal: Le Quellec, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007498/
https://www.ncbi.nlm.nih.gov/pubmed/32099331
http://dx.doi.org/10.2147/DDDT.S167731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007498/
https://www.ncbi.nlm.nih.gov/pubmed/32099331
http://dx.doi.org/10.2147/DDDT.S167731

Ejemplares similares